Skip to content

Jan Thomann

10 papers in the library · 271 citations · publishing 2021-2026

Papers

Sort Most recent Most cited

Acute psilocybin or ethocybin leads to a sustained increase in Pavlovian aversion memory in male mice

Frontiers in Pharmacology September 22, 2026 David Ernst Hogg, Jennifer Romanos, Jamie Albiez et al.

There is considerable interest in the concept that psychedelic compounds might facilitate reorganization of emotional processing with therapeutic benefit; in particular, amelioration of excessive focus on past, current and potential-future aversive events, a dominant emotional-cognitive state in stress-related affective disorders. Translational animal models can advance understanding of...

Acute dose-dependent effects of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) compared with 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin in a double-blind, placebo-controlled study in healthy participants.

Neuropsychopharmacology July 1, 2026 Denis Arikci, Joran Borgulya, Isabelle Straumann et al. 1 citation

Based on its in vitro profile and preliminary evidence, 4-bromo-2,5-dimethoxyphenethylamine (2C-B) may have psychoactive properties that are similar to 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin, which are investigated for the treatment of posttraumatic stress disorder and depressive disorders. We compared acute effects of 2C-B (10, 20, and 30 mg), 125 mg MDMA, and 25 mg psilocybin...

Pharmacokinetics, Pharmacodynamics, and Urinary Recovery of Oral Mescaline Hydrochloride in Healthy Participants.

Clinical Pharmacokinetics July 14, 2025 Lorenz Mueller, Aaron Klaiber, Laura Ley et al. 4 citations

Mescaline is a classic serotonergic psychedelic with a long history of human use. The present study analyzed the pharmacokinetics, pharmacokinetic-pharmacodynamic relationship, and urinary recovery of oral mescaline hydrochloride. Data from 105 single-dose administrations (100-800 mg) in 49 participants from two phase I trials were analyzed with compartmental pharmacokinetics and...

Liquid chromatography-tandem mass spectrometry-based pharmacokinetic and metabolic analysis of 4-bromo-2,5-dimethoxyphenethylamine and its metabolites in human plasma.

Drug Metabolism and Disposition April 28, 2025 Jan Thomann, Deborah Rudin, Selina Kraus et al. 4 citations

4-Bromo-2,5-dimethoxyphenethylamine (2C-B) is widely used recreationally and has recently gained interest as a treatment for mental health disorders. In this study, a liquid chromatography-tandem mass spectrometry method to quantify 2C-B and its metabolites 4-bromo-2,5-dimethoxyphenylacetic acid (BDMPAA) and 4-bromo-2-hydroxy-5-methoxyphenylacetic acid (B-2-HMPAA) in human plasma was developed...

DOI: 10.1016/j.dmd.2025.100086 (opens in new tab) Full text (opens in new tab) Bioanalytical chemistry Bioanalysis Method validation Pharmacokinetics +4

Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre‐Administration in a Randomized, Double‐Blind, Cross‐Over Phase I Trial

Clinical Pharmacology & Therapeutics February 28, 2025 Lorenz Mueller, Alen Jelusic, Avram Tolev et al. 15 citations

Psychedelics, such as psilocybin and lysergic acid diethylamide (LSD), are being investigated for the treatment of depressive and anxiety disorders, for which concomitant treatment with selective serotonin reuptake inhibitors (SSRIs) is prevalent. The present study investigated the acute response to single doses of LSD (100 μg) after daily administration of paroxetine (10 mg for 7 days,...

DOI: 10.1002/cpt.3618 (opens in new tab) Pharmacokinetics Placebo Double blind Pharmacology +5

Acute dose-dependent effects of mescaline in a double-blind placebo-controlled study in healthy subjects.

Translational Psychiatry September 30, 2024 Aaron Klaiber, Yasmin Schmid, Anna M Becker et al. 27 citations

Classic psychedelics have regained interest in research and therapy. Despite the long tradition of the human use of mescaline, modern data on its dose-dependent acute effects and pharmacokinetics are lacking. Additionally, its mechanism of action has not been investigated in humans. We used a randomized, double-blind, placebo-controlled, crossover design in 16 healthy subjects (8 women) who...

Derivatization-free determination of chiral plasma pharmacokinetics of MDMA and its enantiomers.

Journal of Chromatography B May 1, 2024 Dino Luethi, Deborah Rudin, Isabelle Straumann et al. 6 citations

3,4-Methylenedioxymethamphetamine (MDMA) is an entactogen with therapeutic potential. The two enantiomers of MDMA differ regarding their pharmacokinetics and pharmacodynamics but the chiral pharmacology of MDMA needs further study in clinical trials. Here, an achiral and an enantioselective high performance liquid chromatography-tandem mass spectrometry method for the quantification of MDMA and...

DOI: 10.1016/j.jchromb.2024.124123 (opens in new tab) Full text (opens in new tab) Bioanalysis Enantioselective Pharmacokinetics Enantiomers +2

In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin

Frontiers in Pharmacology April 29, 2024 Jan Thomann, Oliver V Stoeckmann, Deborah Rudin et al. 52 citations

In vivo , psilocybin is rapidly dephosphorylated to psilocin which induces psychedelic effects by interacting with the 5-HT 2A receptor. Psilocin primarily undergoes glucuronidation or conversion to 4-hydroxyindole-3-acetic acid (4-HIAA). Herein, we investigated psilocybin’s metabolic pathways in vitro and in vivo , conducting a thorough analysis of the enzymes involved. Metabolism studies were...

DOI: 10.3389/fphar.2024.1391689 (opens in new tab) Psilocybin Metabolite Glucuronidation Cytochrome p450 +8

Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants.

Neuropsychopharmacology October 1, 2023 Laura Ley, Friederike Holze, Denis Arikci et al. 127 citations

Mescaline, lysergic acid diethylamide (LSD), and psilocybin are classic serotonergic psychedelics. A valid, direct comparison of the effects of these substances is lacking. The main goal of the present study was to investigate potential pharmacological, physiological and phenomenological differences at psychoactive-equivalent doses of mescaline, LSD, and psilocybin. The present study used a...

DOI: 10.1038/s41386-023-01607-2 (opens in new tab) Full text (opens in new tab) Psychedelics Hallucinogens Comparative drug research Pharmacology

The Pharmacological Profile of Second Generation Pyrovalerone Cathinones and Related Cathinone Derivative

International Journal of Molecular Sciences July 31, 2021 Karolina E. Kolaczynska, Jan Thomann, Marius C. Hoener et al. 35 citations

Pyrovalerone cathinones are potent psychoactive substances that possess a pyrrolidine moiety. Pyrovalerone-type novel psychoactive substances (NPS) are continuously detected but their pharmacology and toxicology are largely unknown. We assessed several pyrovalerone and related cathinone derivatives at the human norepinephrine (NET), dopamine (DAT), and serotonin (SERT) uptake transporters using...

DOI: 10.3390/ijms22158277 (opens in new tab) Cathinone Pharmacology Potency Dopamine transporter +4